Shattuck Labs Inc logo

STTK

Materials

Shattuck Labs Inc

$6.68+0.14 (+2.14%)PRE

Live · NASDAQ · May 9, Close

AI Insight

What's Moving STTK Today?

No stock-specific AI insight has been generated for STTK yet. Check back soon — insights are generated from recent news analysis.

Fundamentals

Market Cap$505M
P/E Ratio
EPS
Dividend Yield
Dividend / Share
ROE
Profit Margin
Debt / Equity

Trading

Volume442K
Avg Volume (10D)
Shares Outstanding75.6M

STTK News

20 articles

All 20 articles loaded

Price Data

Open$6.50
Previous Close$6.54
Day High$6.76
Day Low$6.33
52 Week High
52 Week Low

About Shattuck Labs Inc

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

40 employees
Listed October 9, 2020
MaterialsPHARMACEUTICAL PREPARATIONS

Company Details

Security TypeStock
ExchangeNASDAQ
Currency
Round Lot
SICPHARMACEUTICAL PREPARATIONS
CIK
Composite FIGI
Share Class FIGI